Quantcast

Latest Opioid antagonists Stories

2014-10-02 08:30:00

LONDON, Oct. 2, 2014 /PRNewswire/ -- Lightlake Therapeutics Inc. ("Lightlake") (OTCQB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that it has closed on investments totaling $1,000,000. The investments were made by an investor in exchange for interests in two different Lightlake products. Lightlake has been developing a nasal spray for the delivery of naloxone that could widely expand its...

2014-09-16 08:32:01

Big Cities Health Coalition Urges Immediate Federal Action WASHINGTON, Sept. 16, 2014 /PRNewswire/ -- Today, the top public health officials from Boston, Chicago, and New York City, all members of the Big Cities Health Coalition, arrived on Capitol Hill with a grim report on the state of opioid addiction and overdose in our nation's cities - and a request for federal action to be taken immediately. "Opioid addiction is one of the most challenging problems for health departments to...

2014-07-30 23:15:52

Mental Health Center at the Cedars-Sinai Medical Towers becomes the first medical practice in Los Angeles to distribute free prescription Naloxone to local treatment centers and sober living facilities. Beverly Hills, CA (PRWEB) July 30, 2014 On January 1, 2014, the Overdose Treatment Act (AB 635) became law in California. The law allows lay people to possess and administer prescription naloxone to someone in urgent need who is experiencing life-threatening respiratory depression from an...

2014-07-30 08:33:40

LONDON, July 30, 2014 /PRNewswire/ -- Lightlake Therapeutics Inc. ("Lightlake") (OTCQB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that it has received a funding commitment from a prominent international research and development foundation. The foundation has a focus on promoting innovative research-based initiatives, including those addressing health issues. Lightlake has been developing a nasal...

2014-07-23 08:31:41

LONDON, July 23, 2014 /PRNewswire/ -- Lightlake Therapeutics Inc. ("Lightlake") (OTCQB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that it has filed an investigational new drug application ("IND") with respect to its naloxone-based opioid overdose reversal nasal spray. Lightlake also announced today that it has received an additional commitment from the National Institute on Drug Abuse ("NIDA"), part...

2014-07-09 08:28:33

LONDON, July 9, 2014 /PRNewswire/ -- Lightlake Therapeutics Inc. ("Lightlake") (OTCQB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that it has signed an agreement with a commercial contract manufacturer to commence production of its naloxone-based opioid overdose reversal treatment. Lightlake expects that this manufacturer will be able to provide sufficient manufacturing capacity at cGMP production...

2014-06-19 16:26:04

SAN FRANCISCO, June 19, 2014 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) reported that partner AstraZeneca today announced that the New England Journal of Medicine (NEJM) has published results of two pivotal Phase III studies - KODIAC-4 and KODIAC-5 of naloxegol, an investigational treatment for opioid-induced constipation (OIC). Opioids play an important role in chronic pain relief by binding to mu-receptors in the brain, but they also bind to mu-receptors in the bowel. That is why...

2014-06-10 08:29:27

RALEIGH, N.C., June 10, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI, will present at two important upcoming healthcare conferences: 34(th) Annual William Blair Growth Stock ConferenceWednesday, June 11, 20143:20 PM Central Time (4:20 PM Eastern Time)Four Seasons Hotel, Chicago, IL Wells Fargo 2014 Healthcare ConferenceTuesday, June 17, 20144:40 PM Eastern...

2014-06-06 23:01:17

A nasal-spray version of Naloxone, a heroin/opiate overdose-reversal drug, is in the works in Kentucky. (PRWEB) June 06, 2014 As reported by USA Today in the article Nasal Spray For Heroin Antidote Under Development(5/31), a Kentucky doctor has been successful in advocating a nasal spray medicine to reverse a heroin or opiate overdose. Dr. Daniel Wermeling has made a deal with a pharmaceutical company to create a nasal spray version of naloxone, a common medicine used on persons who are...

2014-06-05 13:33:09

University of Michigan Health System With naloxegol, adults found relief from opioid-induced constipation Pain medicines often lead to constipation for patients seeking long-term pain relief, but an investigational once-daily drug may help, according to study led by the University of Michigan Health System. Globally, approximately 28 million to 35 million, or nearly half, of patients taking opioids for long-term pain develop constipation. Laxatives provide sub-optimal relief. The...


Word of the Day
barghest
  • A goblin in English folklore, often appearing in the shape of a large dog and believed to portend imminent death or misfortune.
  • A ghost, wraith, hobgoblin, elf, or spirit.
The origin of 'barghest' is not known, but it may be from perhaps burh-ghest, town-ghost, or German Berg-geist (mountain spirit) or Bär-geist (bear-spirit).
Related